Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2019 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter  · In May 2019, Cantargia AB and Patheon Biologics B.V. (a part of ThermoFischer Scientific) signed an agreement on future production of the CAN04 antibody.  · In May 2019, Cantargia announced new preclinical results showing positive effects when the CAN04 antibody is combined with various platinum-based chemotherapies. · New phase I clinical data on Cantargia´s

Ericsson announces changes to the Executive Team

· Fadi Pharaon is appointed Senior Vice President, and Head of Market Area Middle East & Africa, effective September 1, 2019 · Member of Ericsson's Executive Team, reporting to CEOEffective September 1, 2019, Fadi Pharaon is appointed Senior Vice President and Head of Market Area Middle East & Africa at Ericsson (NASDAQ: ERIC), and member of Ericsson’s Executive Team, reporting to the CEO. Fadi Pharaon currently holds the position as Vice President, Networks & Managed Services within Ericsson’s Market Area Europe & Latin America. Börje Ekholm, President and CEO of Ericsson, says: "

ExpreS 2 ion Biotech Holding AB: Publication of interim report for January – June 2019

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby publishes its interim report for the period January – June 2019. The report is available as an attached document to this press release and on the Company’s website (www.expres2ionbio.com). Below is a summary of the report.CEO Steen Klysner comments “The sales and marketing activities initiated in 2018 are beginning to show significant results. Compared to H1 2018 ExpreS[2]ion is able to present a revenue growth of 34 %. During H1 2019 we also witnessed a large and continuous growth in our potential revenue pipeline. We expect to

Interim Report 2, 2019 - Record-breaking quarter strengthens Speqta's preparations for further expansion

Speqta AB (plc) Interim Report for quarter 2, 2019 has now been made public and is available at https://speqta.com/investors/financial-reports Significant events during the period  - Net sales for the second quarter amounted to KSEK 25,633 (13,465), which corresponds to a 90% growth.- Adjusted EBITDA result increased by 115% and amounted to KSEK 5,558 (2,589), which corresponds to an adjusted EBITDA-margin of 22% (19).- Cash flow from operations between April and June 2019 increased and amounted to KSEK 3,477 (244).- The segment Shopping increased sales by 151% to KSEK 20,

Stillfront lists 500 MSEK 5-year senior unsecured bonds on the Frankfurt Stock Exchange Open Market

NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SWITZERLAND, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL Pressrelease Stockholm 2019-08-22Stillfront Group AB (publ) (“Stillfront” or the “Company”) has successfully listed its MSEK 500 senior unsecured bonds due 2024 (the “Bonds”) on the Open Market of the Frankfurt Stock Exchange (Freiverkehr). The Company is pleased to announce that the Bonds have

Dignitana AB Publishes Q2 2019 Interim Report

Financial highlights ·  Total revenue for the Group amounted to 12,002 TSEK, 1,275 KUSD which is an increase of 33 percent over the same period 2018. ·  Year to date revenue for the Group was 22,109 TSEK, 2,350 KUSD, an increase of 47 percent over the same period 2018. Business highlights   ·  FDA clearance of the next generation DigniCap Delta June 2019.   ·  First European installation of DigniCap Delta at Gemelli University Hospital in Rome, Italy, in May 2019.   ·  Contracts were signed for 19 locations in the United States, bringing the total number of signed U.S.

Half-Year Report 1 January 2019 – 30 June 2019

Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes the Half-Year Report for the period 1 January – 30 June 2019. The Half-Year Report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.Reporting period April 2019 – June 2019 · Net sales amounted to DKK 0 (0). · Operating profit was -4.851m DKK (-2.366). · Cash and bank assets amounted to 3.160 m DKK (327). · Result per share was DKK -0.33 (-0.23). Reporting period January 2019 – June 2019 · Net sales amounted to DKK 0 (0). · Operating profit

InCoax Networks AB’s Interim Report, January – June 2019

Several evaluation studies were initiated and the first commercial installations of In:xtnd™ in Europe are under way.Financial performance April–June 2019 · Net sales amounted to SEK 1,108,187 (525,851), which is equivalent to an increase of 111% compared with the corresponding period in the preceding year. · The company posted an operating loss of SEK –18,654,944 (–11,647,705), a reduction driven primarily by organizational growth. · The loss after tax was SEK –18,695,898 (–11,701,346), corresponding to earnings per share of SEK –1.51 (–1.75). · Cash flow including financing

NOTICE OF EXTRAORDINARY SHAREHOLDERS’ MEETING IN INCOAX NETWORKS AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders of InCoax Network AB, Reg. No. 556794-1363, are hereby invited to attend the extraordinary shareholders’ meeting to be held at the company’s premises at Utmarksvägen 4 in Gävle, on Monday 9 September 2019, at 1.00 p.m.Right to participate and notification Shareholders wishing to participate in the meeting must: · partly be listed in the company’s share register kept by Euroclear Sweden AB as of Tuesday 3

Moberg Pharma’s Year-end report to be published on August 29 - Invitation to teleconference

STOCKHOLM, August 22th, 2019 - On August 29th 2019, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Year-end report 2019. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English. Date:             August 29th, 2019Time:             3:00 pm (CET) To participate in the conference, please dial in on any number below before the start of the call: SE:

Flexion Mobile Plc - Q1 Report 30 June 2019

Flexion delivers a solid quarter and continues to expand its portfolio of games. During the first quarter of the new financial year, IAP (In-App Purchase) revenue increased by 39% to GBP 1.9m compared to the same period last year and total annual revenue increased by 35% to GBP 1.9m. The Company signed its second biggest top-tier title and one mid-tier game while also launching three of its signed top-tier games.April 2019 to June 2019 performance · IAP (In App Purchase) revenue increased by 39% to GBP 1.9m (GBP 1.3m*) · Total revenue increased by 35% to GBP 1.9m (GBP 1.4m) ·

AstraZeneca agrees to buy US FDA Priority Review

22 August 2019 07:00 BST AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi AstraZeneca today announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi). A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval. The transaction is subject to clearance under the Hart-Scott

Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease

22 August 2019 07:00 BST Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease China is the first country to approve roxadustat for all chronic kidney disease patients with anaemia AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients. This approval, granted by the National

Inhalation Sciences Sweden AB (publ) releases Half Year Report Q2 2019

Inhalation Sciences CEO Lena Heffler: “A major milestone was reached this quarter with the announcement that we’re commencing a new Study validating PreciseInhale for clinical use. We also received a purchase order for a second PreciseInhale system from a client, a landmark for the company. With clinical validation started and DissolvIt on the way towards commercialization, our goal continues to be achieving cash flow positive results on a full-year basis during 2020.”Summary of the Reporting period Highlights during Inhalation Sciences Sweden AB's second quarter: · On May 7, ISAB

Interim report

January 1 – June 30, 2019The second quarter in figures · Net sales amounted to TSEK 2,168 (1,571). · The loss after tax amounted to TSEK 10,613 (10,298). · The loss per share amounted to SEK 0.64 (0.62). · The cash flow from current operations was negative in the amount of TSEK 9,900 (10,119). · The gross margin reached 53.3% (58.2%). · Electrode sales volume increased by 33% and reached 5,712 (4,304) units. Repeat sales of electrodes to existing customers increased by 41%. The first half-year in figures ·  Net sales amounted to TSEK 4,536 (3,510). ·  The loss

NENT Group takes hold of ‘Seizure’ as latest Norwegian original series

· Supernatural drama stars Anders Danielsen Lie and Anders Baasmo Christiansen · ‘Seizure’ premieres exclusively on Viaplay on 31 October · NENT Group to premiere at least 20 original productions every year The next original series from Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, is Norwegian supernatural drama ‘Seizure’. The eight-part show is NENT Group’s first Norwegian original to reach viewers since the success of ‘Wisting’ and will premiere exclusively on NENT Group’s Viaplay streaming service across the Nordic region on 31 October.

Sobi has entered into agreement to sell Priority Review Voucher

Swedish Orphan Biovitrum AB (publ)  (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 M. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval. The PRV was acquired as part of the acquisition of

Phase III study of Mangoral to start in H2-2019

Ascelia Pharma AB (publ) (ticker: ACE) today announced that its full-year report for the period July 2018 - June 2019 is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q4 (APRIL-JUNE 2019) · Encouraging results from Oncoral’s Phase I combination study with oral capecitabine · Supportive feedback from EMA on the Phase III program for Mangoral · New patent application filed for Mangoral with potential to extend IP rights to year 2040 · IPO overallotment utilised raising SEK 22 million FINANCIAL SUMMARY IN Q4 (

3rd Quarter Results

To view the Q3 2019 Report to Shareholders in PDF, please click on the link below.       http://www.rns-pdf.londonstockexchange.com/rns/8459J_1-2019-8-21.pdf    Royal Bank of Canada third quarter 2019 results    All amounts are in Canadian dollars and are based on financial statements prepared in compliance with International Accounting Standard 34 Interim Financial Reporting, unless otherwise noted.     Net Income $3.3 Diluted  ROE(2) 16.7% Balanced   CET1 Billion Diversified EPS(1) $2.22 Solid  capital deployment     Ratio 11.9%

Orkla invests in Iceland’s best-known chocolate brand

Orkla ASA has signed an agreement to purchase 20% of the Icelandic company Nói-Siríus HF (“Nói Siríus”), Iceland’s leading chocolate and confectionery manufacturer. Nói Siríus is market leader in Iceland, and well known for chocolate brands such as Síríus, Nóa Konfekt, Nóa Kropp, Nóa Páskaegg and Konsum. Over 70% of the company’s turnover is generated by domestic market sales. Moreover, a growing percentage of the company’s sales are export and tax-free sales. The business also distributes some strong, global brands of chocolate, snacks and breakfast products.  Orkla operates in

Systemair's Interim Report for the first quarter will be presented on August 29

Press Release, 22 August 2019 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2019/20 will be published at 13:00 CET on August 29, 2019. A telephone conference will be held at 13:30 CET on August 29, 2019. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO. In order to participate in the telephone conference:Call +46 8 566 426 51 and enter code 68101761# minutes before start. The presentation will be published on group.systemair.com For further information contact:Roland Kasper, CEO, + 46 73 094 40 13, +46 222 440

SinterCast Results April-June 2019

25% increase in year-on-year series production Second Quarter 2019 · Revenue for Period: SEK 33.5 million (SEK 26.8 million) · Operating Result: SEK 12.9 million (SEK 11.0 million) · Earnings per Share: SEK 2.0 per share (SEK 1.6 per share) · Cashflow from Operations: SEK 7.2 million (SEK 3.2 million) · Record annualised series production of 3.4 million Engine Equivalents in second quarter · Record annualised monthly production of 3.5 million Engine Equivalents in May · Installation revenue in second quarter surpasses previous full-year average 2019 Year-to-Date

Change in Board of Directors of Basware

Basware Corporation, stock exchange release, August 22, 2019 at 8:45 am EESTMrs. Tuija Soanjärvi, member of the Board since 2013 and chairman of the Audit committee, has decided to reduce her board memberships due to personal reasons and has resigned from the Board of Directors of Basware as of August 21, 2019. “We wish to thank Tuija Soanjärvi for her strong and successful contribution to developing Basware into a world leading company in its field”, said Ilkka Sihvo, Chairman of the Board of Directors. After the change, the Board of Directors of Basware has five members. David

Continued adjustment with clear targets in sight

· Net sales decreased with 1% to SEK 238 million (240). · EBIT amounted to SEK -1.5 million (20.7), corresponding to a margin of -0.6% (8.7). · Earnings per share amounted to SEK -0.66 (0.35). · The average income per member and month increased with 1 per cent to SEK 352 (350). In today’s interim year report, Actic Group reports a negative growth of 1% in the second quarter. EBIT amounted to SEK -1.5 million with a negative margin of 0.6%. The result has been affected by the restructuring work during the second quarter, which resulted in additional costs totaling nearly SEK 12

There are no items matching the current filter
There are no more items matching the current filter
Back to top